Piper Sandler downgraded Verona Pharma (VRNA) to Neutral from Overweight with a price target of $107, down from $160, after Merck (MRK) announced it will acquire Verona for $10B or $107 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA: